Bone marrow stromal mesenchymal cells induce down regulation of CD20 expression on B-CLL: Implications for rituximab resistance in CLL

British Journal of Haematology

Volumn 169, Issue 2, 2015, Pages 211-218

  Marquez, Maria Elena ^a   Hernández Uzcátegui, Octavio ^a   Cornejo, Alejandro ^a   Vargas, Paula ^a   Da Costa, Osiris ^b  

^a INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

^b Banco Munic Sangre Distrito F   (Venezuela)

Author keywords

CD20; Chronic lymphocytic leukaemia; Mesenchymal stromal cells; Rituximab

Indexed keywords

CD20 ANTIGEN; CD59 ANTIGEN; RITUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW STROMA CELL; CELL INTERACTION; CELL ISOLATION; CHRONIC LYMPHATIC LEUKEMIA; COCULTURE; DOWN REGULATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; MESENCHYMAL STROMA CELL; PRIORITY JOURNAL; REGULATORY MECHANISM; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CELL COMMUNICATION; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION; GENETICS; IMMUNOLOGY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD20; ANTIGENS, CD59; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL COMMUNICATION; COCULTURE TECHNIQUES; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MESENCHYMAL STROMAL CELLS;

EID: 84926420163     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13286     Document Type: Article

References (26)

1. Bonavida, B. (2007) Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene, 26, 3629-3636.
2. Burger, J.A. (2011) Nurture versus nature: the microenvironment in chronic lymphocytic leukemia. Hematology American Society of Hematology Education Program, 2011, 96-103.
3. Burger, J.A. & Montserrat, E. (2013) Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling. Blood, 121, 1501-1509.
4. Burger, J.A., Tsukada, N., Burger, M., Zvaifler, N.J., Dell'Aquila, M. & Kipps, T.J. (2000) Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood, 96, 2655-2663.
5. Burger, J.A., Ghia, P., Rosenwald, A. & Caligaris-Cappio, F. (2009) The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood, 114, 3367-3375.
6. Caligaris-Cappio, F. (2003) Role of the microenvironment in chronic lymphocytic leukaemia. British Journal of Haematology, 123, 380-388.
7. Cragg, M., Walshe, C., Ivanov, A. & Glennie, M. (2005) The biology of CD20 and its potential as a target for mAb therapy. Current Directions in Autoimmunity, 8, 140-174.
8. Dighiero, G. & Hamblin, T.J. (2008) Chronic lymphocytic leukaemia. Lancet, 371, 1017-1029.
9. Ding, W., Nowakowski, G.S., Knox, T.R., Boysen, J.C., Maas, M.L., Schwager, S.M., Wu, W., Wellik, L.E., Dietz, A.B., Ghosh, A.K., Secreto, C.R., Medina, K.L., Shanafelt, T.D., Zent, C.S., Call, T.G. & Kay, N.E. (2009) Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression. British Journal of Haematology, 147, 471-483.
10. Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F., Krause, D., Deans, R., Keating, A., Prockop, D. & Horwitz, E. (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8, 315-317.
11. Fischer, L., Penack, O., Gentilini, C., Nogai, A., Muessig, A., Thiel, E. & Uharek, L. (2006) The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells. Experimental Hematology, 34, 753-759.
12. Golay, J., Zaffaroni, L., Vaccari, T., Lazzari, M., Borleri, G.M., Bernasconi, S., Tedesco, F., Rambaldi, A. & Introna, M. (2000) Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood, 95, 3900-3908.
13. Golay, J., Lazzari, M., Facchinetti, V., Bernasconi, S., Borleri, G., Barbui, T., Rambaldi, A. & Introna, M. (2001) CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood, 98, 3383-3389.
14. Hallek, M., Cheson, B.D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Dohner, H., Hillmen, P., Keating, M.J., Montserrat, E., Rai, K.R., Kipps, T.J. & International Workshop on Chronic Lymphocytic, L. (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood, 111, 5446-5456.
15. Hoogduijn, M.J., Popp, F., Verbeek, R., Masoodi, M., Nicolaou, A., Baan, C. & Dahlke, M.H. (2010) The immunomodulatory properties of mesenchymal stem cells and their use for immunotherapy. International Immunopharmacology, 10, 1496-1500.
16. Hu, W., Ge, X., You, T., Xu, T., Zhang, J., Wu, G., Peng, Z., Chorev, M., Aktas, B.H., Halperin, J.A., Brown, J.R. & Qin, X. (2011) Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis. Cancer Research, 71, 2298-2307.
17. Huh, Y., Keating, M., Saffer, H., Jilani, I., Lerner, S. & Albitar, M. (2011) Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia. American Journal of Clinical Pathology, 116, 437-443.
18. Kay, N.E., Shanafelt, T.D., Strege, A.K., Lee, Y.K., Bone, N.D. & Raza, A. (2007) Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an "angiogenic switch". Leukemia Research, 31, 899-906.
19. Kurtova, A.V., Balakrishnan, K., Chen, R., Ding, W., Schnabl, S., Quiroga, M.P., Sivina, M., Wierda, W.G., Estrov, Z., Keating, M.J., Shehata, M., Jager, U., Gandhi, V., Kay, N.E., Plunkett, W. & Burger, J.A. (2009) Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood, 114, 4441-4450.
20. Marquez, M.E.E., Deglesne, P.A.A., Suarez, G. & Romano, E. (2011) MFI ratio estimation of ZAP-70 in B-CLL by flow cytometry can be improved by considering the isotype-matched antibody signal. International journal of laboratory hematology, 33, 194-200.
21. Marquez, M.-E.E., Deglesne, P.-A.A., Lopez, J.L., Da Costa, O., Borrego, M., Hernández, M., Muller, A., Ajchenbaum-Cymbalista, F. & Romano, E. (2012) Unexpectedly high frequency of European parentage in VENn patients with chronic lymphocytic leukemia. Leukemia & Lymphoma, 53, 235-241.
22. Shanafelt, T.D., Geyer, S.M., Bone, N.D., Tschumper, R.C., Witzig, T.E., Nowakowski, G.S., Zent, C.S., Call, T.G., Laplant, B., Dewald, G.W., Jelinek, D.F. & Kay, N.E. (2008) CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential. British Journal of Haematology, 140, 537-546.
23. Smith, M.R. (2003) Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene, 22, 7359-7368.
24. Spiller, O.B., Criado-Garcia, O., Rodriguez De Cordoba, S. & Morgan, B.P. (2000) Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma cells from complement attack. Clinical and Experimental Immunology, 121, 234-241.
25. Takei, K., Yamazaki, T., Sawada, U., Ishizuka, H. & Aizawa, S. (2006) Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines. Leukemia Research, 30, 625-631.
26. Weng, W.K. & Levy, R. (2001) Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood, 98, 1352-1357.